Is empiric daptomycin effective in reducing mortality in Staphylococcus aureus bacteraemia? A real-life experience

Intensive Care Medicine

Volumn 41, Issue 11, 2015, Pages 2026-2028

  Bassetti, Matteo ^a,c   Ansaldi, Filippo ^b   De Florentiis, Daniela ^b   Righi, Elda ^a   Pea, Federico ^c   Sartor, Assunta ^a   Scarparo, Claudio ^a   Carnelutti, Alessia ^a  

^a S Maria Hospital   (Italy)

^b UNIVERSITY OF GENOA   (Italy)

^c SANTA MARIA DELLA MISERICORDIA UNIVERSITY HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

DAPTOMYCIN; ANTIINFECTIVE AGENT;

ANTIBIOTIC THERAPY; DRUG EFFICACY; DRUG MEGADOSE; HUMAN; LETTER; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; METHICILLIN SUSCEPTIBLE STAPHYLOCOCCUS AUREUS; MORTALITY; PRESCRIPTION; STAPHYLOCOCCAL BACTEREMIA; AGED; BACTEREMIA; COMORBIDITY; DRUG EFFECTS; FEMALE; HOSPITAL MORTALITY; ITALY; MALE; MIDDLE AGED; RETROSPECTIVE STUDY; RISK FACTOR; SEVERITY OF ILLNESS INDEX; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS; STATISTICAL MODEL; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; BACTEREMIA; COMORBIDITY; DAPTOMYCIN; FEMALE; HOSPITAL MORTALITY; HUMANS; ITALY; LOGISTIC MODELS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; RISK FACTORS; SEVERITY OF ILLNESS INDEX; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS;

EID: 84942500762     PISSN: 03424642     EISSN: 14321238     Source Type: Journal    
DOI: 10.1007/s00134-015-4021-9     Document Type: Letter

References (5)

1. Bassetti M, Trecarichi EM, Mesini A, Spanu T, Giacobbe DR, Rossi M, Shenone E, Pascale GD, Molinari MP, Cauda R, Viscoli C, Tumbarello M (2012) Risk factors and mortality of healthcare-associated and community-acquired Staphylococcus aureus bacteraemia. Clin Microbiol Infect 18:862–869
2. Moore CK, Osaki-Kiyan P, Haque NZ, Perri MB, Donabedian S, Zervos MJ (2012) Daptomycin versus vancomycin for bloodstream infections due to methicillin-resistant Staphylococcus aureus with a high vancomycin minimum inhibitory concentration: a case-control study. Clin Infect Dis 54:51–58
3. Bassetti M, Nicco E, Ginocchio F, Ansaldi F, de Florentiis D, Viscoli C (2010) High-dose daptomycin in documented Staphylococcus aureus infections. Int J Antimicrob Agents 36:459–461
4. Bassetti M, Villa G, Ansaldi F, De Florentiis D, Tascini C, Cojutti P, Righi E, Sartor A, Crapis M, De Rosa FG, Pea F, Menichetti F (2015) Risk factors associated with the onset of daptomycin non-susceptibility in Staphylococcus aureus infections in critically ill patients. Intensive Care Med 41:366–368
5. Lodise TP Jr, McKinnon PS, Levine DP, Rybak MJ (2007) Impact of empirical-therapy selection on outcomes of intravenous drug users with infective endocarditis caused by methicillin-susceptible Staphylococcus aureus. Antimicrob Agents Chemother 51:3731–3733